Navigation Links
ViiV Healthcare Starts Phase III Clinical Programme of Celsentri/Selzentry® (maraviroc) versus Truvada® (tenofovir + FTC), in combination with a Protease Inhibitor in people living with HIV
Date:10/11/2011

LONDON, Oct. 11, 2011 /PRNewswire/ -- ViiV Healthcare announces the start of the Phase III MODERN Study [Maraviroc Once daily with Darunavir Enhanced by Ritonavir in a Novel regimen], also known as A4001095, comparing its CCR5-inhibitor, Celsentri/Selzentry® (maraviroc), to emtricitabine/tenofovir (Truvada®), both in combination with darunavir/ritonavir. The 96-week trial will evaluate a two-drug versus three-drug once-daily regimen for the treatment of antiretroviral-naive patients infected with CCR5-tropic HIV-1.

"The treatment of HIV has come a long way, but it is essential that we continue to pursue effective novel treatment strategies that minimise toxicity while maximising tolerability and convenience. The MODERN study will investigate a treatment approach using Celsentri that is designed to meet those goals," said Dr. John Pottage, Chief Scientific and Medical Officer, ViiV Healthcare. "ViiV Healthcare is committed to understanding patient needs and addressing them through innovative treatment approaches that directly reflect what we learn."

Exploration of HIV treatment regimens that don't include a nucleoside reverse transcriptase inhibitor (NRTI), currently recommended as part of standard of care for first line HIV therapy, continues to be an area of interest because of the potential to alleviate some long-term toxicities associated with NRTI-based regimens and preserve future treatment options.  

About MODERNMODERN is a Phase III, 96-week, multi-center, randomised, double-blind, comparative study. It will include approximately 804 antiretroviral-naive patients infected with CCR5-tropic HIV-1 from over 250 sites in the E.U., U.S. and Australia. The primary endpoint for MODERN is the proportion of patients with HIV-1 RNA <50 copies/mL at week 48. Secondary objectives include the proportion of patients with HIV-1 RNA below the limits of assay detection at week 96; change in CD4+ and CD8+ cell counts through 48 an
'/>"/>

SOURCE ViiV Healthcare
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. MSC to Offer Surgical Implant Cost Management Solution through Acquisition of Integrated Healthcare Services
2. Medicalbillersandcoders.com Offers Effective Ways to Combat Healthcare Fraud and Abuse in California, Florida, and Michigan
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. GNS Healthcare, Inc Collaborates with Nationally Ranked Hospital to Predict Adverse Drug Events and Hospital Readmissions
5. Tengion to Present at Rodman & Renshaw 13th Annual Healthcare Conference
6. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
7. Chimerix to Present at Stifel Nicolaus 2011 Healthcare Conference
8. Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
9. Neuralstem President and CEO to Present at the 2011 Stifel Nicolaus Annual Healthcare Conference
10. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
11. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... CINCINNATI , April 16, 2015  Schulman Associates ... and technology, has signed a long-term lease on Laboratory ... Park, North Carolina . The location will house ... located to provide high quality reviews and customer service ... Raleigh represented Schulman in the deal, while ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... 2015 A new infographic compiles useful ... research institutions to learn how Apple’s new framework can ... timing is ideal since Apple made Research Kit ... an open-source framework for developing medical research apps that ... for researchers to collect secure clinical data and communicate ...
(Date:4/16/2015)... Switzerland , April 16, 2015 ... of Debiopharm Group ™ , a Swiss-based global ... unmet medical needs as well as companion ... the investigational compounds Debio 1143 (SMAC mimetic) and ... at the 2015 Annual meeting of the ...
Breaking Biology Technology:Schulman IRB to Open Office in Research Triangle Park, N.C. 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 2Debiopharm International SA Announces Results of 2 Key Oncology Programs at 2015 AACR Conference 3
... WALTHAM, Mass., Nov. 10, 2011 Interleukin Genetics, Inc. ... the third quarter ended September 30, 2011. Total ... $765,000, compared to $545,000 for the same period in the ... revenue. Research and development expenses were $325,000 ...
... Inc., a global, full-service testing laboratory with more than ... organs, cells, tissues and implantable biologic products and devices, ... private companies, as judged by the annual ColoradoBiz ... Top 250 Private Companies list is an annual ranking ...
... England Biolabs (NEB), in its continuing commitment to open ... database covering DNA polymerase biochemistry, genetics and structural biology. ... and maintained by NEB), Polbase summarizes the information that ... it easy for researchers to interrogate and use. Polbase ...
Cached Biology Technology:Interleukin Genetics Reports Third Quarter 2011 Financial Results 2Interleukin Genetics Reports Third Quarter 2011 Financial Results 3Interleukin Genetics Reports Third Quarter 2011 Financial Results 4LABS, Inc. Among Colorado's Top Private Companies 2New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers 2
(Date:3/20/2015)... , March 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... is one of the products featured in 2015 "I ... at 11:00 PM EST on the DIY Network.   ... Las Vegas , site of the 2015 ...
(Date:3/19/2015)... Conn. , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, announces ... in a news clip that aired this week on ... ) . In a segment "The Next Great ... wallet ,a new way to pay, and ,a really big ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... press release is available in French . ... an expert multinational team battling the global spread of drug-resistant ... treatment. Better understanding of the make-up of these parasites and ... by John Dalton, a biochemist in McGill,s Institute of Parasitology, ...
... the University of Sheffield has shown for the first time ... nutritional status of older people with dementia. The ... Geriatric Psychiatry and funded by the National Health Research ... the eating patterns of dementia patients in Taiwan. Loss ...
... Australia,s own distinctive red soils could play a part ... algae often shovelled off east coast beaches in summer., A ... how iron, which gives our iron-rich soil its red colour, ... not only have a foul smell, but also make our ...
Cached Biology News:New method improves eating skills of dementia patients 2Is iron from soil a factor in algal blooms? 2
Rabbit polyclonal to FOXJ2 ( Abpromise for all tested applications). entrezGeneID: 55810 SwissProtID: Q9P0K8...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Macrophage-stimulating protein receptor...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
Biology Products: